Ligand-receptor interactions of the low density lipoprotein receptor-related protein, a multi-ligand endocytic receptor

Fibrinolysis and Proteolysis

Volumn 12, Issue 4, 1998, Pages 219-240

  Neels, J G ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN RECEPTOR;

CARBOXY TERMINAL SEQUENCE; CELL GROWTH; CELL MIGRATION; DRUG RECEPTOR BINDING; ENDOCYTOSIS; ENDOPLASMIC RETICULUM; GENE STRUCTURE; HUMAN; HUMAN TISSUE; LIGAND BINDING; LIPOPROTEIN METABOLISM; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN LIPID INTERACTION; PROTEIN SYNTHESIS REGULATION; REVIEW;

EID: 0031736170     PISSN: 13690191     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(98)80016-7     Document Type: Review

References (273)

1. Herz J, Hamann U, Rogne S, Myklebost O, Gausepohl H, Stanley KK. Surface location and high affinity for calcium of a 500-kd liver membrane protein closely related to the LDL-
2. receptor suggest a physiological role as lipoprotein receptor. EMBO J 1988; 7: 4119-4127.
3. Moestrup SK. The alpha 2-macroglobulin receptor and epithelial glycoprotein-330: two giant receptors mediating endocytosis of multiple ligands. Biochim Biophys Acta 1994; 1197: 197-213.
4. Krieger M, Herz J. Structures and functions of multiligand lipoprotein receptors: macrophage scavenger receptors and LDL receptor-related protein (LRP). Annu Rev Biochem 1994; 63: 601-637.
5. Strickland DK, Kounnas MZ, Williams SE, Argraves WS. LDL receptor-related protein (LRP): a multiligand receptor. Fibrinolysis 1994; 8 (Suppl 1): 204-215.
6. Strickland DK, Kounnas MZ, Argraves WS. LDL receptor-related protein: a multiligand receptor for lipoprotein and proteinase catabolism. FASEB J 1995; 9: 890-898.
7. Moestrup SK Gliemann J. Purification of the rat hepatic alpha 2-macroglobulin receptor as an approximately 440-kDa single chain protein. J Biol Chem 1989; 264: 15574-15577.
8. Ashcom JD, Tiller SE, Dickerson K et al. The human alpha 2-macroglobulin receptor: identification of a 420-kD cell surface glycoprotein specific for the activated conformation of alpha 2-macroglobulin. J Cell Biol 1990; 110: 1041-1048.
9. Strickland DK, Ashcom JD, Williams S et al. Sequence identity between the alpha 2-macroglobulin receptor and low density lipoprotein receptor-related protein suggests that this molecule is a multifunctional receptor. J Biol Chem 1990; 265: 17401-17404.
10. Kristensen T, Moestrup SK, Gliemann J, Bendtsen L, Sand O, Sottrup-Jensen L. Evidence that the newly cloned low-density-lipoprotein receptor related protein (LRP) is the alpha 2-macroglobulin receptor. FEBS Lett 1990; 276: 151-155.
11. Hilliker C, Van Leuven F, Van den Berghe H. Assignment of the gene coding for the alpha 2-macroglobulin receptor to mouse chromosome 15 and to human chromosome 12q13-q14 by isotopic and nonisotopic in situ hybridization. Genomics 1992; 13: 472-474.
12. Myklebost O, Arheden K, Rogne S et al. The gene for the human putative apoE receptor is on chromosome 12 in the segment q 13-14. Genomics 1989; 5: 65-69.
13. Van Leuven F, Stas L, Hilliker C et al. Structure of the gene (LRP1) coding for the human alpha 2-macroglobulin receptor lipoprotein receptor-related protein. Genomics 1994; 24: 78-89.
14. Herz J, Kowal RC, Goldstein JL, Brown MS. Proteolytic processing of the 600 kd low density lipoprotein receptor-related protein (LRP) occurs in a trans-Golgi compartment. EMBO J 1990; 9: 1769-1776.
15. Jensen PH, Gliemann J, Ørntoft T. Characterization of carbohydrates in the alpha 2-macroglobulin receptor. FEBS Lett 1992; 305: 129-132.
16. Willnow TE, Moehring JM, Inocencio NM, Moehring TJ, Herz J. The low-density-lipoprotein receptor-related protein (LRP) is processed by furin in vivo and in vitro. Biochem J 1996; 313: 71-76.
17. Chen WJ, Goldstein JL, Brown MS. NPXY, a sequence often found in cytoplasmic tails, is required for coated pit-mediated internalization of the low density lipoprotein receptor. J Biol Chem 1990; 265: 3116-3123.
18. Herz J, Kowal RC, Ho YK, Brown MS, Goldstein JL. Low density lipoprotein receptor-related protein mediates endocytosis of monoclonal antibodies in cultured cells and rabbit liver. J Biol Chem 1990; 265: 21355-21362.
19. Moestrup SK, Gliemann J, Pallesen G. Distribution of the alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein in human tissues. Cell Tissue Res 1992; 269: 375-382.
20. Birkenmeier G, Grosche J, Reichenbach A. Immunocytochemical demonstration of alpha 2-M-R/LRP on Muller (glial) cells isolated from rabbit and human retina. Neuroreport 1996; 8: 149-151.
21. Howard GC, Roberts BC, Epstein DL, Pizzo SV. Characterization of alpha 2-macroglobulin binding to human trabecular meshwork cells: presence of the alpha 2-macroglobulin signaling receptor. Arch Biochem Biophys 1996; 333: 19-26.
22. Descamps O, Bilheimer D, Herz J. Insulin stimulates receptor-mediated uptake of apoE-enriched lipoproteins and activated alpha 2-macroglobulin in adipocytes. J Biol Chem 1993; 268: 974-981.
23. Igdoura SA, Argraves WS, Morales CR et al. Low density lipoprotein receptor-related protein-1 expression in the testis - Regulated expression in sertoli cells. J Androl 1997; 18: 400-410.
24. Moestrup SK, Kaltoft K, Petersen CM et al. Immunocytochemical identification of the human alpha 2-macroglobulin receptor in monocytes and fibroblasts: monoclonal antibodies define the receptor as a monocyte differentiation antigen. Exp Cell Res 1990; 190: 195-203.
25. Watanabe Y, Inaba T, Shimano H et al. Induction of LDL receptor-related protein during the differentiation of monocyte-macrophages. Possible involvement in the atherosclerotic process. Arteriosclerosis & Thrombosis 1994; 14: 1000-1006.
26. Hussaini IM, Srikumar K, Quesenberry PJ, Gonias SL. Colony-stimulating factor-1 modulates alpha 2-macroglobulin receptor expression in murine bone marrow macrophages. J Biol Chem 1990; 265: 19441-19446.
27. Garner B, Baoutina A, Dean RT, Jessup W. Regulation of serum-induced lipid accumulation in human monocyte-derived macrophages by interferon-gamma. Correlations with apolipoprotein E production, lipoprotein lipase activity and LDL receptor-related protein expression. Atherosclerosis 1997; 128: 47-58.
28. Szanto A, Balasubramaniam S, Roach PD, Nestel PJ. Modulation of the low-density- lipoprotein-receptor-related protein and its relevance to chylomicron-remnant metabolism. Biochem J 1992; 288: 791-794.
29. Hussaini IM, LaMarre J, Lysiak JJ, Karns LR, VandenBerg SR, Gonias SL. Transcriptional regulation of LDL receptor-related protein by IFN-gamma and the antagonistic activity of TGF-beta(1) in the RAW 264.7 macrophage-like cell line. J Leukoc Biol 1996; 59: 733-739.
30. LaMarre J, Wolf BB, Kittler EL, Quesenberry PJ, Gonias SL. Regulation of macrophage alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein by lipopolysaccharide and interferon-gamma. J Clin Invest 1993; 91: 1219-1224.
31. Businaro R, Fabrizi C, Persichini T et al. Modulation of the alpha 2 macroglobulin receptor/low density lipoprotein receptor related protein by interferon-gamma in human astroglial cells. J Neuroimmunol 1997; 72: 75-81.
32. Corvera S, Graver DF, Smith RM. Insulin increases the cell surface concentration of alpha 2-macroglobulin receptors in 3T3-L1 adipocytes. Altered transit of the receptor among intracellular endocytic compartments. J Biol Chem 1989; 264: 10133-10138.
33. Weaver AM, McCabe M, Kim I, Allietta MM, Gonias SL. Epidermal growth factor and platelet-derived growth factor-BB induce a stable increase in the activity of low density lipoprotein receptor-related protein in vascular smooth muscle cells by altering receptor distribution and recycling. J Biol Chem 1996; 271: 24894-24900.
34. Gåfvels ME, Coukos G, Sayegh R et al. Regulated expression of the trophoblast alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Differentiation and cAMP modulate protein and mRNA levels. J Biol Chem 1992; 267: 21230-21234.
35. Kütt H, Herz J, Stanley KK. Structure of the low-density lipoprotein receptor-related protein (LRP) promoter. Biochim Biophys Acta 1989; 1009: 229-236.
36. Herz J, Clouthier DE, Hammer RE. LDL receptor-related protein internalizes and degrades uPA-PAI-1 complexes and is essential for embryo implantation [published erratum appeared in Cell 1993 May 7;73(3):428]. Cell 1992; 71: 411-421.
37. Herz J, Couthier DE, Hammer RE. Correction: LDL receptor-related protein internalizes and degrades uPA-PAl-1 complexes and is essential for embryo implantation [letter]. Cell 1993; 73: 428
38. Beisiegel U, Weber W, Ihrke G, Herz J, Stanley KK. The LDL-receptor-related protein, LRP, is an apolipoprotein E-binding protein. Nature 1989; 341: 162-164.
39. Kowal RC, Herz J, Goldstein JL, Esser V, Brown MS. Low density lipoprotein receptor-related protein mediates uptake of cholesteryl esters derived from apoprotein E-enriched lipoproteins. PNAS 1989; 86: 5810-5814.
40. Nykjær A, Bengtsson-Olivecrona G, Lookene A et al. The alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein binds lipoprotein lipase and beta-migrating very low density lipoprotein associated with the lipase. J Biol Chem 1993; 268: 15048-15055.
41. Chappell DA, Fry GL, Waknitz MA, Iverius PH, Williams SE, Strickland DK. The low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor binds and mediates catabolism of bovine milk lipoprotein lipase. J Biol Chem 1992; 267: 25764-25767
42. Chappell DA, Fry GL, Waknitz MA, Muhonen LE, Pladet MW, Iverius PH, Strickland DK. Lipoprotein lipase induces catabolism of normal triglyceride-rich lipoproteins via the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor in vitro. A process facilitated by cell-surface proteoglycans. J Biol Chem 1993; 268: 14168-14175.
43. Kounnas MZ, Chappell DA, Wong H, Argraves WS, Strickland DK. The cellular internalization and degradation of hepatic lipase is mediated by low density lipoprotein receptor-related protein and requires cell surface proteoglycans. J Biol Chem 1995; 270: 9307-9312.
44. Lund H, Takahashi K, Hamilton RL, Havel RJ. Lipoprotein binding and endosomal itinerary of the low density lipoprotein receptor-related protein in rat liver. PNAS 1989; 86: 9318-9322.
45. Hussain MM, Maxfield FR, Mas-Oliva J et al. Clearance of chylomicron remnants by the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor. J Biol Chem 1991; 266: 13936-13940.
46. Beisiegel U, Weber W, Bengtsson-Olivecrona G. Lipoprotein lipase enhances the binding of chylomicrons to low density lipoprotein receptor-related protein. PNAS 1991; 88: 8342-8346.
47. Chappell DA, Inoue 1, Fry GL et al. Cellular catabolism of normal very low density lipoproteins via the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor is induced by the C-terminal domain of lipoprotein lipase. J Biol Chem 1994; 269: 18001-18006.
48. Williams SE, Inoue I, Tran H et al. The carboxyl-terminal domain of lipoprotein lipase binds to the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor (LRP) and mediates binding of normal very low density lipoproteins to LRP. J Biol Chem 1994; 269: 8653-8658.
49. Goldstein JL, Brown MS. Familiar hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, ed. The Metabolic-Basis of Inherited Disease. New York: McGraw-Hill Publishing Company, 1989; 1215-1250.
50. Willnow TE, Sheng Z, Ishibashi S, Herz J. Inhibition of hepatic chylomicron remnant uptake by gene transfer of a receptor antagonist. Science 1994; 264: 1471-1474.
51. Liao W. Beta-migrating very-low-density lipoprotein, chylomicron remnants and their receptors. Biochem J 1995; 310: 359.
52. Ishibashi S, Herz J, Maeda N, Goldstein JL, Brown MS. The two-receptor model of lipoprotein clearance: tests of the hypothesis in knockout mice lacking the low density lipoprotein receptor, apolipoprotein E, or both proteins. PNAS 1994; 91: 4431-4435.
53. Mokuno H, Brady S, Kotite L, Herz J, Havel RJ. Effect of the 39-kDa receptor-associated protein on the hepatic uptake and endocytosis of chylomicron remnants and low density lipoproteins in the rat. J Biol Chem 1994; 269: 13238-13243.
54. Rohlmann A, Gotthardt M, Hammer RE, Herz J. Inducible inactivation of hepatic LRP gene by Cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants. J Clin Invest 1998; 101: 689-695.
55. Luoma J, Hiltunen T, Särkioja T et al. Expression of alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein and scavenger receptor in human atherosclerotic lesions. J Clin Invest 1994; 93: 2014-2021.
56. Lupu F, Heim D, Bachmann F, Kruithof EK. Expression of LDL receptor-related protein/alpha 2-macroglobulin receptor in human normal and atherosclerotic arteries. Arteriosclerosis & Thrombosis 1994; 14: 1438-1444.
57. Carrell RW, Boswell DR. Serpins: the superfamily of plasma serine proteinase inhibitors. In: Barrett AJ, Salvesen G, ed. Proteinase inhibitors. Amsterdam: Elsevier, 1986; 403-420.
58. Orth K, Madison EL, Gething MJ, Sambrook JF, Herz J. Complexes of tissue-type plasminogen activator and its serpin inhibitor plasminogen-activator inhibitor type 1 are internalized by means of the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor. PNAS 1992; 89: 7422-7426.
59. Bu G, Williams S, Strickland DK, Schwartz AL. Low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor is an hepatic receptor for tissue-type plasminogen activator. PNAS 1992; 89: 7427-7431.
60. Kounnas MZ, Henkin J, Argraves WS, Strickland DK. Low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor mediates cellular uptake of prourokinase. J Biol Chem 1993; 268: 21862-21867.
61. Nykjær A, Petersen CM, Moller B et al. Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase. plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes. J Biol Chem 1992; 267: 14543-14546.
62. Conese M, Olson D, Blasi F. Protease nexin-1-urokinase complexes are internalized and degraded through a mechanism that requires both urokinase receptor and alpha 2-macroglobulin receptor. J Biol Chem 1994; 269: 17886-17892.
63. Strickland DK and Kounnas MZ. Mechanisms of cellular uptake of thrombin-antithrombin III complexes - Role of the low-density lipoprotein receptor-related protein as a serpinenzyme complex receptor. Trends in Cardiovascular Medicine 1997; 7: 9-16.
64. Danø K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985; 44: 139-266.
65. Moscatelli D Rifkin DB. Membrane and matrix localization of proteinases: a common theme in tumor cell invasion and angiogenesis. Biochim Biophys Acta 1988; 948: 67-85.
66. Kirchheimer JC Remold HG. Endogenous receptor-bound urokinase mediates tissue invasion of human monocytes. J Immunol 1989; 143: 2634-2639.
67. Sappino AP, Huarte J, Belin D, Vassalli JD. Plasminogen activators in tissue remodeling and invasion: mRNA localization in mouse ovaries and implanting embryos. J Cell Biol 1989; 109: 2471-2479.
68. Baker MS, Bleakley P, Woodrow GC, Doe WF. Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation. Cancer Research 1990; 50: 4676-4684.
69. Fazioli F Blasi F. Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy?. Trends Pharmacol Sci 1994; 15: 25-29.
70. Andreasen PA, Sottrup-Jensen L, Kjøller L et al. Receptor-mediated endocytosis of plasminogen activators and activator/inhibitor complexes. FEBS Lett 1994; 338: 239-245.
71. Nykjær A, Kjøller L, Cohen RL et al. Regions involved in binding of urokinase-type-1 inhibitor complex and prourokinase to the endocytic alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that the urokinase receptor protects pro-urokinase against binding to the endocytic receptor. J Biol Chem 1994; 269: 25668-25676.
72. Nykjær A, Conese M, Christensen El et al. Recycling of the urokinase receptor upon internalization of the uPA: serpin complexes. EMBOJ 1997; 16: 2610-2620.
73. Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman HA. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 1994; 269: 32380-32388.
74. Weaver AM, Hussaini IM, Mazar A, Henkin J, Gonias SL. Embryonic fibroblasts that are genetically deficient in low density lipoprotein receptor-related protein demonstrate increased activity of the urokinase receptor system and accelerated migration on vitronectin. J Biol Chem 1997; 272: 14372-14379.
75. Wijnberg MJ, Quax PHA, Nieuwenbroek NME, Verheijen JH. The migration of human smooth muscle cells in vitro is mediated by plasminogen activation and can be inhibited by alpha(2)-macroglobulin receptor associated protein. Thromb Haemost 1997; 78: 880-886.
76. Bonner JC, Badgett A, Huffman M, Lindroos PM. Inhibition of platelet-derived growth factor-BB-induced fibroblast proliferation by plasmin-activated alpha 2-macroglobulin is mediated via an alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein-dependent mechanism. J Biol Chem 1995; 270: 6389-6395.
77. Phillips DJ, Mcfarlane JR, Hearn MTW, Dekretser DM. Inhibin, activin and follistatin bind preferentially to the transformed species of alpha(2)-macroglobulm. J Endocrinol 1997; 155: 65-71.
78. LaMarre J, Hayes MA, Wollenberg GK, Hussaini I, Hall SW, Gonias SL. An alpha 2-macroglobulin receptor-dependent mechanism for the plasma clearance of transforming growth factor-beta 1 in mice. J Clin Invest 1991; 87: 39-44.
79. Warshawsky I, Broze GJ, Jr., Schwartz AL. The low density lipoprotein receptor-related protein mediates the cellular degradation of tissue factor pathway inhibitor. PNAS 1994; 91: 6664-6668.
80. Moestrup SK, Gui S, Vorum H et al. Evidence that epithelial glycoprotein 330/megalin mediates uptake of polybasic drugs [see comments]. J Clin Invest 1995; 96: 1404-1413.
81. Kounnas MZ, Moir RD, Rebeck GW et al. LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted beta-amyloid precursor protein and mediates its degradation. Cell 1995; 82: 331-340.
82. Rebeck GW, Reiter JS, Strickland DK, Hyman BT. Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron 1993; 11: 575-580.
83. Rebeck GW, Harr SD, Strickland DK, Hyman BT. Multiple, diverse senile plaque-associated proteins are ligands of an apolipoprotein E receptor, the alpha 2-macroglobulin receptor/low-density-lipoprotein receptor-related protein. Ann Neurol 1995; 37: 211-217
84. Collen D, Lijnen HR. Molecular basis of fibrinolysis, as relevant for thrombolytic therapy. Thromb Haemost 1995; 74: 167-171.
85. Nykjaer A, Kjøller L, Cohen RL, Lawrence DA, Gliemann J, Andreasen PA. Both pro-uPA and uPA: PAI-1 complex bind to the alpha 2-macroglobulin receptor/LDL receptor-related protein. Evidence for multiple independent contacts between the ligands and receptor. Ann N Y Acad Sci 1994; 737: 483-485.
86. Kuiper J, Otter M, Rijken DC, van Berkel TJ. Characterization of the interaction in vivo of tissue-type plasminogen activator with liver cells. J Biol Chem 1988; 263: 18220-18224.
87. Warshawsky I, Bu G, Schwanz AL. 39-kD protein inhibits tissue-type plasminogen activator clearance in vivo. J Clin Invest 1993; 92: 937-944.
88. van der Kaaden ME, Rijken DC, Kruijt JK, van Berkel TJ, Kuiper J. The role of the low-density lipoprotein receptor-related protein (LRP) in the plasma clearance and liver uptake of recombinant single-chain urokinase-type plasminogen activator in rats. Thromb Haemost 1997; 77: 710-717.
89. Godyna S, Liau G, Popa I, Stefansson S, Argraves WS. Identification of the low density lipoprotein receptor-related protein (LRP) as an endocytic receptor for thrombospondin-1. J Cell Biol 1995; 129: 1403-1410.
90. Mikhailenko I, Kounnas MZ, Strickland DK. Low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor mediates the cellular internalization and degradation of thrombospondin. A process facilitated by cell-surface proteoglycans. J Biol Chem 1995; 270: 9543-9549.
91. Chen H, Strickland DK, Mosher DR Metabolism of thrombospondin 2. Binding and degradation by 3t3 cells and glycosaminoglycan-variant Chinese hamster ovary cells. J Biol Chem 1996; 271: 15993-15999.
92. Leung LL. Role of thrombospondin in platelet aggregation. J Clin Invest 1984; 74: 1764-1772.
93. Silverstein RL, Leung LL, Nachman RL. Thrombospondin: a versatile multifunctional glycoprotein. Arteriosclerosis 1986; 6: 245-253.
94. Adams JC Lawler J. Diverse mechanisms for cell attachment to platelet thrombospondin. J Cell Sci 1993; 104: 1061-1071.
95. Roberts DD, Sherwood JA, Ginsburg V. Platelet thrombospondin mediates attachment and spreading of human melanoma cells. J Cell Biol 1987; 104: 131-139.
96. Lawler J, Weinstein R, Hynes RO. Cell attachment to thrombospondin: the role of ARG-GLY-ASP, calcium, and integrin receptors. J Cell Biol 1988; 107: 2351-2361.
97. Kaesberg PR, Ershler WB, Esko JD, Mosher DF. Chinese hamster ovary cell adhesion to human platelet thrombospondin is dependent on cell surface heparan sulfate proteoglycan. J Clin Invest 1989; 83: 994-1001.
98. Murphy-Ullrich JE, Hook M. Thrombospondin modulates focal adhesions in endothelial cells. J Cell Biol 1989; 109: 1309-1319.
99. Majack RA, Cook SC, Bornstein P. Control of smooth muscle cell growth by components of the extracellular matrix: autocrine role for thrombospondin. PNAS 1986; 83: 9050-9054.
100. Majack RA, Goodman LV, Dixit VM. Cell surface thrombospondin is functionally essential for vascular smooth muscle cell proliferation. J Cell Biol 1988; 106: 415-422.
101. Phan SH, Dillon RG, McGarry BM, Dixit VM. Stimulation of fibroblast proliferation by thrombospondin. Biochem Biophys Res Comm 1989; 163: 56-63.
102. Good DJ, Polverini PJ, Rastinejad F et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. PNAS 1990; 87: 6624-6628.
103. Hogg PJ. Thrombospondin 1 as an enzyme inhibitor. Thromb Haemost 1994; 72: 787-792.
104. Anonick PK, Yoo JK, Webb DJ, Gonias SL. Characterization of the antiplasmin activity of human thrombospondin-1 in solution. Biochem J 1993; 289: 903-909.
105. Kounnas MZ, Morris RE, Thompson MR, FitzGerald DJ, Strickland DK, Saelinger CB. The alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein binds and internalizes Pseudomonas exotoxin A. J Biol Chem 1992; 267: 12420-12423.
106. Hofer F, Gruenberger M, Kowalski H et al. Members of the low density lipoprotein receptor family mediate cell entry of a minor-group common cold virus. PNAS 1994; 91: 1839-1842.
107. Shakibaei M, Frevert U. Dual interaction of the malaria circumsporozoite protein with the low density lipoprotein receptor-related protein (LRP) and heparan sulfate proteoglycans. J Exp Med 1996; 184: 1699-1711.
108. Cavallaro U, Nykjær A, Nielsen M, Soria MR. Alpha 2-macroglobulin receptor mediates binding and cytotoxicity of plant ribosome-inactivating proteins. Eur J Biochem 1995; 232: 165-171.
109. Willnow TE, Goldstein JL, Orth K, Brown MS, Herz J. Low density lipoprotein receptor-related protein and gp330 bind similar ligands, including plasminogen activator-inhibitor complexes and lactoferrin, an inhibitor of chylomicron remnant clearance. J Biol Chem 1992; 267: 26172-26180.
110. Bu G Rennke S. Receptor-associated protein is a folding chaperone for low density lipoprotein receptor-related protein. J Biol Chem 1996; 271: 22218-22224.
111. Obermoeller LM, Warshawsky I, Wardell MR, Bu G. Differential functions of triplicated repeats suggest two independent roles for the receptor-associated protein as a molecular chaperone. J Biol Chem 1997; 272: 10761-10768.
112. Kounnas MZ, Argraves WS, Strickland DK. The 39-kDa receptor-associated protein interacts with two members of the low density lipoprotein receptor family, alpha 2-macroglobulin receptor and glycoprotein 330. J Biol Chem 1992; 267: 21162-21166.
113. Herz J, Goldstein JL, Strickland DK, Ho YK, Brown MS. 39-kDa protein modulates binding of ligands to low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor. J Biol Chem 1991; 266:21232-21238.
114. Williams SE, Ashcom JD, Argraves WS, Strickland DK. A novel mechanism for controlling the activity of alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Multiple regulatory sites for 39-kDa receptor-associated protein. J Biol Chem 1992; 267: 9035-9040.
115. Stifani S, Barber DL, Aebersold R et al. The laying hen expresses two different low density lipoprotein receptor-related proteins. J Biol Chem 1991; 266: 19079-19087.
116. Moestrup SK, Holtet TL, Etzerodt M et al. Alpha 2-macroglobulin-proteinase complexes, plasminogen activator inhibitor type-1-plasminogen activator complexes, and receptor-associated protein bind to a region of the alpha 2-macroglobulin receptor containing a cluster of eight complement-type repeats. J Biol Chem 1993; 268: 13691-13696.
117. Willnow TE, Orth K, Herz J. Molecular dissection of ligand binding sites on the low density lipoprotein receptor-related protein. J Biol Chem 1994; 269: 15827-15832.
118. Esser V, Limbird LE, Brown MS, Goldstein JL, Russell DW. Mutational analysis of the ligand binding domain of the low density lipoprotein receptor. J Biol Chem 1988; 263: 13282-13290.
119. Russell DW, Brown MS, Goldstein JL Different combinations of cysteine-rich repeats mediate binding of low density lipoprotein receptor to two different proteins. J Biol Chem 1989; 264: 21682-21688.
120. Horn IR, van den Berg BMM, van der Meijden PZ, Pannekoek H, van Zonneveld AJ. Molecular analysis of ligand binding to the second cluster of complement-type repeats of the low density lipoprotein receptor-related protein. Evidence for an allosteric component in receptor-associated protein-mediated inhibition of ligand binding. J Biol Chem 1997; 272: 13608-13613.
121. Orlando RA, Exner M, Czekay RP et al. Identification of the second cluster of ligand-binding repeats in megalin as a site for receptor-ligand interactions. PNAS 1997; 94: 2368-2373.
122. Davis CG, Goldstern JL, Südhof TC et al. Acid-dependent ligand dissociation and recycling of LDL receptor mediated by growth factor homology region. Nature 1987; 326: 760-765.
123. Südhof TC, Goldstein JL, Brown MS, Russell DW. The LDL receptor gene: a mosaic of exons shared with different proteins. Science 1985; 228: 815-822.
124. Yamamoto T, Davis CG, Brown MS et al. The human LDL receptor: a cysteine-rich protein with multiple Alu sequences in its mRNA. Cell 1984; 39: 27-38.
125. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232: 34-47.
126. Sakai J, Hoshino A, Takahashi S et al. Structure, chromosome location, and expression of the human very low density lipoprotein receptor gene. J Biol Chem 1994; 269: 2173-2182.
127. Kasza A, Petersen HH, Heegaard CW et al. Specificity of serine proteinase serpin complex binding to very-low-density lipoprotein receptor and alpha(2)-macroglobulin receptor low-density-lipoprotein-receptor-related protein. Eur J Biochem 1997; 248: 270-281.
128. Takahashi S, Kawarabayasi Y, Nakai T, Sakai J, Yamamoto, T. Rabbit very low density lipoprotein receptor: a low density lipoprotein receptor-like protein with distinct ligand specificity. PNAS 1992; 89: 9252-9256.
129. Argraves KM, Battey FD, MacCalman CD et al. The very low density lipoprotein receptor mediates the cellular catabolism of lipoprotein lipase and urokinase-plasminogen activator inhibitor type I complexes. J Biol Chem 1995; 270: 26550-26557
130. Kim DH, Iijima H, Goto K et al. Human apolipoprotein E receptor 2. A novel lipoprotein receptor of the low density lipoprotein receptor family predominantly expressed in brain. J Biol Chem 1996; 271: 8373-8380.
131. Hjalm G, Murray E, Crumley G et al. Cloning and sequencing of human gp330, a Ca(2+)-binding receptor with potential intracellular signaling properties. Eur J Biochem 1996; 239: 132-137
132. Stefansson S, Chappell DA, Argraves KM, Strickland DK, Argraves WS. Glycoprotein 330/low density lipoprotein receptor-related protein-2 mediates endocytosis of low density lipoproteins via interaction with apolipoprotein B100. J Biol Chem 1995; 270: 19417-19421.
133. Moestrup SK, Birn H, Fischer PB et al. Megalin-mediated endocytosis of transcobalamin-vitamin-B12 complexes suggests a role of the receptor in vitamin-B 12 homeostasis. PNAS 1996; 93: 8612-8617
134. Yochem J, Greenwald I. A gene for a low density lipoprotein receptor-related protein in the nematode Caenorhabditis elegans. PNAS 1993; 90: 4572-4576.
135. Schonbaum CP, Lee S, Mahowald AP. The Drosophila yolkless gene encodes a vitellogenin receptor belonging to the low density lipoprotein receptor superfamily. PNAS 1995; 92: 1485-1489.
136. Nimpf J, Schneider WJ. The chicken LDL receptor-related protein/alpha 2-macroglobulin receptor family. Ann N Y Acad Sci 1994; 737: 145-153.
137. Jacobsen L, Madsen P, Moestrup SK et al. Molecular characterization of a novel human hybrid-type receptor that binds the alpha(2)-macroglobulin receptor-associated protein. J Biol Chem 1996; 271: 31379-31383.
138. Yamazaki H, Bujo H, Kusunoki J et al. Elements of neural adhesion molecules and a yeast vacuolar protein sorting receptor are present in a novel mammalian low density lipoprotein receptor family member. J Biol Chem 1996; 271: 24761-24768.
139. Tensen CP, Van Kesteren ER, Planta RJ et al. A G protein-coupled receptor with low density lipoprotein-binding motifs suggests a role for lipoproteins in G-linked signal transduction. PNAS 1994; 91: 4816-4820.
140. Catterall CF, Lyons A, Sim RB, Day AJ, Harris TJ. Characterization of primary amino acid sequence of human complement control protein factor I from an analysis of cDNA clones. Biochem J 1987; 242: 849-856.
141. Goldberger G, Bruns GA, Rits M, Edge MD, Kwiatkowski DJ. Human complement factor I: analysis of cDNA-derived primary structure and assignment of its gene to chromosome 4. J Biol Chem 1987; 262: 10065-10071.
142. Dewald G, Nothen MM, Cichon S. Polymorphism of human complement component C6: an amino acid substitution (Glu/Ala) within the second thrombospondin repeat differentiates between the two common allotypes Co A and C6 B. Biochem Biophys Res Comm 1993; 194: 458-464.
143. DiScipio RG, Chakravarti DN, Muller-Eberhard HJ, Fey GH. The structure of human complement component C7 and the C5b-7 complex. J Biol Chem 1988; 263: 549-560.
144. Rao AG, Howard OM, Ng SC, Whitehead AS, Cölten HR, Sodetz JM. Complementary DNA and derived amino acid sequence of the alpha subunit of human complement protein C8: evidence for the existence of a separate alpha subunit messenger RNA. Biochemistry 1987; 26: 3556-3564.
145. Howard OM, Rao AG, Sodetz JM. Complementary DNA and derived amino acid sequence of the beta subunit of human complement protein C8: identification of a close structural and ancestral relationship to the alpha subunit and C9. Biochemistry 1987; 26: 3565-3570.
146. Haefliger JA, Tschopp J, Nardelli D et al. Complementary DNA cloning of complement C8 beta and its sequence homology to C9. Biochemistry 1987; 26: 3551-3556.
147. Stanley KK, Kocher HP, Luzio JP, Jackson P, Tschopp J. The sequence and topology of human complement component C9. EMBO J 1985; 4: 375-382.
148. Cohen IR, Grassel S, Murdoch AD, lozzo RV. Structural characterization of the complete human perlecan gene and its promoter. PNAS 1993; 90: 10404-10408.
149. Rogalski TM, Williams BD, Mullen GP, Moerman DG. Products of the unc-52 gene in Caenorhabditis elegans are homologous to the core protein of the mammalian basement membrane heparan sulfate proteoglycan. Genes & Development 1993; 7: 1471-1484.
150. Suzuki T, Takagi T, Ohta S. N-terminal amino acid sequence of the deep-sea tube worm haemoglobin remarkably resembles that of annelid haemoglobin. Biochem J 1988; 255: 541-545.
151. Suzuki T, Takagi T, Gotoh T. Primary structure of two linker chains of the extracellular hemoglobin from the polychaete Tylorrhynchus heterochaetus. J Biol Chem 1990; 265: 12168-12177
152. Kitamoto Y, Yuan X, Wu Q, McCourt DW, Sadler JE. Enterokinase, the initiator of intestinal digestion, is a mosaic protease composed of a distinctive assortment of domains. PNAS 1994; 91: 7588-7592.
153. Nagase T, Seki N, Ishikawa K, Tanaka A, Nomura N. Prediction of the coding sequences of unidentified human genes. V. The coding sequences of 40 new genes (KIAA0161-KIAA0200) deduced by analysis of cDNA clones from human cell line KG-1. DNA Res 1996; 3: 17-24.
154. Hong CC, Hashimoto C. An unusual mosaic protein with a protease domain, encoded by the nudel gene, is involved in defining embryonic dorsoventral polarity in Drosophila. Cell 1995; 82: 785-794.
155. Bates P, Young JA, Varmus HE. A receptor for subgroup A rous sarcoma virus is related to the low density lipoprotein receptor. Cell 1993; 74: 1043-1051.
156. Suzuki T, Riggs AF. Linker chain LI of earthworm hemoglobin. Structure of gene and protein: homology with low density lipoprotein receptor. J Biol Chem 1993; 268: 13548-13555.
157. Bieri S, Djordjevic JT, Daly NL, Smith R, Kroon PA. Disulfide bridges of a cysteine-rich repeat of the LDL receptor ligand-binding domain. Biochemistry 1995; 34: 13059-13065.
158. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988; 240: 622-630.
159. Goldstein JL, Brown MS, Anderson RG, Russell DW, Schneider WJ. Receptor-mediated endocytosis: concepts emerging from the LDL receptor system. Annu Rev Cell Biol 1985; 1: 1-39.
160. van Driel IR, Goldstein JL, Südhof TC, Brown MS. First cysteine-rich repeat in ligand-binding domain of low density lipoprotein receptor binds Ca2+ and monoclonal antibodies, but not lipoproteins. J Biol Chem 1987; 262: 17443-17449.
161. Moestrup SK, Kaltoft K, Sottrup-Jensen L, Gliemann J. The human alpha 2-macroglobulin receptor contains high affinity calcium binding sites important for receptor conformation and ligand recognition. J Biol Chem 1990; 265: 12623-12628.
162. Daly NL, Scanlon MJ, Djordjevic JT, Kroon PA, Smith R. Three-dimensional structure of a cysteine-rich repeat from the low-density lipoprotein receptor. PNAS 1995; 92: 6334-6338.
163. Daly NL, Djordjevic JT, Kroon PA, Smith R. Three-dimensional structure of the second cysteine-rich repeat from the human low-density lipoprotein receptor. Biochemistry 1995; 34: 14474-14481.
164. Fass D, Blacklow S, Kim PS, Berger JM. Molecular basis of familial hypercholesterolaemia from structure of LDL receptor module [see comments]. Nature 1997; 388: 691-693.
165. Beisiegel U, Schneider WJ, Goldstein JL, Anderson RG, Brown MS. Monoclonal antibodies to the low density lipoprotein receptor as probes for study of receptor-mediated endocytosis and the genetics of familial hypercholesterolemia. J Biol Chem 1981; 256: 11923-11931.
166. Daniel TO, Schneider WJ, Goldstein JL, Brown MS. Visualization of lipoprotein receptors by ligand blotting. J Biol Chem 1983; 258: 4606-4611.
167. Horn IR, Moestrup SK, van den Berg BMM, Pannekoek H, Nielsen MS, van Zonneveld AJ. Analysis of the binding of prourokinase and urokinase-plasminogen activator inhibitor-1 complex to the low density lipoprotein receptor-related protein using a Fab fragment selected from a phage-displayed Fab library. J Biol Chem 1995; 270: 11770-11775.
168. Kounnas MZ, Church FC, Argraves WS, Strickland DK. Cellular internalization and degradation of antithrombin III-thrombin, heparin cofactor II-thrombin, and alpha 1-antitrypsin-trypsin complexes is mediated by the low density lipoprotein receptor-related protein. J Biol Chem 1996; 271: 6523-6529.
169. Hüettinger M, Retzek H, Hermann M, Goldenberg H. Lactoferrin specifically inhibits endocytosis of chylomicron remnants but not alpha-macroglobulin. J Biol Chem 1992; 267: 18551-18557
170. Moestrup SK, Gliemann J. Analysis of ligand recognition by the purified alpha 2-macroglobulin receptor (low density lipoprotein receptor-related protein). Evidence that high affinity of alpha 2-macroglobulin-proteinase complex is achieved by binding to adjacent receptors. J Biol Chem 1991; 266: 14011-14017.
171. Ji ZS, Fazio S, Lee YL, Mahley RW. Secretion-capture role for apolipoprotein E in remnant lipoprotein metabolism involving cell surface heparan sulfate proteoglycans. J Biol Chem 1994; 269: 2764-2772.
172. Yokoyama S, Kawai Y, Tajima S, Yamamoto A. Behavior of human apolipoprotein E in aqueous solutions and at interfaces. J Biol Chem 1985; 260: 16375-16382.
173. Aggerbeck LP, Wetterau JR, Weisgraber KH, Wu CS, Lindgren FT. Human apolipoprotein E3 in aqueous solution. II. Properties of the amino- and carboxyl-terminal domains. J Biol Chem 1988; 263: 6249-6258.
174. Yokoyama S. Self-associated tetramer of human apolipoprotein E does not lead to its accumulation on a lipid particle. Biochim Biophys Acta 1990; 1047: 99-101.
175. Wetterau JR, Aggerbeck LP, Rail SC, Jr. Human apolipoprotein E3 in aqueous solution. I. Evidence for two structural domains. J Biol Chem 1988; 263: 6240-6248.
176. Innerarity TL, Friedlander EJ, Rail SC, Jr, Mahley RW. The receptor-binding domain of human apolipoprotein E. Binding of apolipoprotein E fragments. J Biol Chem 1983; 258: 12341-12347
177. Wilson C, Wardell MR, Weisgraber KH, Mahley RW, Agard DA. Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E. Science 1991; 252: 1817-1822.
178. Weisgraber KH, Innerarity TL, Harder KJ et al. The receptor-binding domain of human apolipoprotein E. Monoclonal antibody inhibition of binding. J Biol Chem 1983; 258: 12348-12354.
179. Mahley RW, Innerarity TL, Pitas RE, Weisgraber KH, Brown JH, Gross E. Inhibition of lipoprotein binding to cell surface receptors of fibroblasts following selective modification of arginyl residues in arginine-rich and B apoproteins. J Biol Chem 1977; 252: 7279-7287.
180. Weisgraber KH, Innerarity TL, Mahley RW. Role of lysine residues of plasma lipoproteins in high affinity binding to cell surface receptors on human fibroblasts. J Biol Chem 1978; 253: 9053-9062.
181. Cardin AD, Hirose N, Blankenship DT et al. Binding of a high reactive heparin to human apolipoprotein E: identification of two heparin-binding domains. Biochem Biophys Res Comm 1986; 134: 783-789.
182. Weisgraber KH, Rail SC, Jr, Mahley RW et al. Human apolipoprotein E. Determination of the heparin binding sites of apolipoprotein E3. J Biol Chem 1986; 261: 2068-2076.
183. Mahley RW, Weisgraber KH, Innerarity TL. Interaction of plasma lipoproteins containing apolipoproteins B and E with heparin and cell surface receptors. Biochim Biophys Acta 1979; 575: 81-91.
184. Utermann G, Langenbeck U, Beisiegel U, Weber W. Genetics of the apolipoprotein E system in man. Am J Hum Genet 1980; 32: 339-347.
185. Zannis VI, Breslow JL. Human very low density lipoprotein apolipoprotein E isoprotein polymorphism is explained by genetic variation and posttranslational modification. Biochemistry 1981; 20: 1033-1041.
186. Weisgraber KH, Rall SC, Jr., Mahley RW. Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. J Biol Chem 1981; 256: 9077-9083.
187. Weisgraber KH, Innerarity TL, Mahley RW. Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J Biol Chem 1982; 257: 2518-2521.
188. Kowal RC, Herz J, Weisgraber KH, Mahley RW, Brown MS, Goldstein JL. Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein. J Biol Chem 1990; 265: 10771-10779.
189. Winkler FK, D'Arcy A, Hunziker W. Structure of human pancreatic lipase. Nature 1990; 343: 771-774.
190. van Tilbeurgh H, Roussel A, Lalouel JM, Cambillau C. Lipoprotein lipase. Molecular model based on the pancreatic lipase x-ray structure: consequences for heparin binding and catalysis. J Biol Chem 1994; 269: 4626-4633.
191. Osborne JC, Jr., Bengtsson-Olivecrona G, Lee NS, Olivecrona T. Studies on inactivation of lipoprotein lipase: role of the dimer to monomer dissociation. Biochemistry 1985; 24: 5606-5611.
192. Tornvall P, Olivecrona G, Karpe F, Hamsten A, Olivercrona T. Lipoprotein lipase mass and activity in plasma and their increase after heparin are separate parameters with different relations to plasma lipoproteins. Arteriosclerosis, Thrombosis & Vascular Biology 1995; 15: 1086-1093.
193. Ma Y, Henderson HE, Liu MS et al. Mutagenesis in four candidate heparin binding regions (residues 279-282, 291-304, 390-393, and 439-448) and identification of residues affecting heparin binding of human lipoprotein lipase. J Lipid Res 1994; 35: 2049-2059.
194. Dugi KA, Dichek HL, Santamarina-Fojo S. Human hepatic and lipoprotein lipase: the loop covering the catalytic site mediates lipase substrate specificity. J Biol Chem 1995; 270: 25396-25401.
195. Santamarina-Fojo S, Dugi KA. Structure, function and role of lipoprotein lipase in lipoprotein metabolism. Curr Opin Lipid 1994; 5: 117-125.
196. Nykjær A, Nielsen M, Lookene A et al. A carboxyl-terminal fragment of lipoprotein lipase binds to the low density lipoprotein receptor-related protein and inhibits lipase-mediated uptake of lipoprotein in cells. J Biol Chem 1994; 269: 31747-31755.
197. Krapp A, Zhang H, Ginzinger D et al. Structural features in lipoprotein lipase necessary for the mediation of lipoprotein uptake into cells. J Lipid Res 1995; 36: 2362-2373.
198. Nielsen MS, Brejning J, Garcia R et al. Segments in the C-terminal folding domain of lipoprotein lipase important for binding to the low density lipoprotein receptor-related protein and to heparan sulfate proteoglycans. J Biol Chem 1997; 272: 5821-5827.
199. Grobmyer SR, Kuo A, Orishimo M, Okada SS, Cines DB, Barnathan ES. Determinants of binding and internalization of tissue-type plasminogen activator by human vascular smooth muscle and endothelial cells. J Biol Chem 1993; 268: 13291-13300.
200. Camani C, Bachmann F, Kruithof EK. The role of plasminogen activator inhibitor type 1 in the clearance of tissue-type plasminogen activator by rat hepatoma cells. J Biol Chem 1994; 269: 5770-5775.
201. Fa M, Karolin J, Aleshkov S, Strandberg L, Johansson LB, Ny T. Time-resolved polarized fluorescence spectroscopy studies of plasminogen activator inhibitor type 1 : conformational changes of the reactive center upon interactions with target proteases, vitronectin and heparin. Biochemistry 1995; 34: 13833-13840.
202. Shore JD, Day DE, Francis-Chmura AM et al. A fluorescent probe study of plasminogen activator inhibitor-1. Evidence for reactive center loop insertion and its role in the inhibitory mechanism. J Biol Chem 1995; 270: 5395-5398.
203. Debrock S, Declerck PJ. Characterization of common neoantigenic epitopes generated in plasminogen activator inhibitor-1 after cleavage of the reactive center loop or after complex formation with various serine proteinases. FEBS Lett 1995; 376: 243-246.
204. Egelund R, Schousboe SL, Sottrup-Jensen L et al. Type-1 plasminogen-activator inhibitor - conformational differences between latent, active, reactive-centre-cleaved and plasminogen-activator-complexed forms, as probed by proteolytic susceptibility. Eur J Biochem 1997; 248: 775-785.
205. Stefansson S, Lawrence DA, Argraves WS. Plasminogen activator inhibitor-1 and vitronectin promote the cellular clearance of thrombin by low density lipoprotein receptor-related proteins 1 and 2. J Biol Chem 1996; 271: 8215-8220.
206. Wing LR, Hawksworth GM, Bennett B, Booth NA. Clearance of t-PA, PAI-1, and t-PA-PAI-1 complex in an isolated perfused rat liver system. J Lab Clin Med 1991; 117: 109-114.
207. Stefansson S, Muhammad S, Lawrence DA. Clearance studies of PAI-1 : protease complexes suggest that PAI-1 contains a cryptic LRP binding site. Fibrinolysis 1996; 10: 11
208. Keijer J, Linders M, Wegman JJ, Ehrlich HJ, Mertens K, Pannekoek H. On the target specificity of plasminogen activator inhibitor 1 : the role of heparin, vitronectin, and the reactive site. Blood 1991; 78: 1254-1261.
209. Rodenburg KW, Kjø1ler L, Petersen HH, Andreasen PA. Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha-2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor. Biochem J 1998; 329: 55-63.
210. Stein P, Chothia C. Serpin tertiary structure transformation. J Mol Biol 1991; 221: 615-621.
211. Lawrence DA, Berkenpas MB, Palaniappan S, Ginsburg D. Localization of vitronectin binding domain in plasminogen activator inhibitor-1. J Biol Chem 1994; 269: 15223-15228.
212. Knauer MF, Hawley SB, Knauer DJ. Identification of a binding site in protease nexin I (PN1) required for the receptor mediated internalization of PN1-thrombin complexes. J Biol Chem 1997; 272: 12261-12264.
213. Rovelli G, Stone SR, Guidolin A, Sommer J, Monard D. Characterization of the heparin-binding site of glia-derived nexin/protease nexin-1. Biochemistry 1992; 31: 3542-3549.
214. Zhang LT, Strickland DK, Cines DB, Higazi AAR. Regulation of single chain urokinase binding, internalization, and degradation by a plasminogen activator inhibitor 1-derived peptide. J Biol Chem 1997; 272: 27053-27057
215. Sottrup-Jensen L. Alpha-macroglobulins: structure, shape, and mechanism of proteinase complex formation. J Biol Chem 1989; 264: 11539-11542.
216. Van Leuven F, Marynen P, Sottrup-Jensen L, Cassiman JJ, Van den Berghe H. The receptor-binding domain of human alpha 2-macroglobulin. Isolation after limited proteolysis with a bacterial proteinase. J Biol Chem 1986; 261: 11369-11373.
217. Sottrup-Jensen L, Gliemann J, Van Leuven F. Domain structure of human alpha 2-macroglobulin. Characterization of a receptor-binding domain obtained by digestion with papain. FEBS Lett 1986; 205: 20-24.
218. Nielsen KL, Sottrup-Jensen L, Fey GH, Thogersen HC. Expression and refolding of a high-affinity receptor binding domain from rat alpha 1-macroglobulin. FEBS Lett 1995; 373: 296-298.
219. Holtet TL, Nielsen KL, Etzerodt M et al. Receptor-binding domain of human alpha 2-macroglobulin. Expression, folding and biochemical characterization of a high-affinity recombinant derivative. FEBS Lett 1994; 344: 242-246.
220. Marynen P, Van Leuven F, Cassiman JJ, Van den Berghe H. Pi-oteolysis at a lysine residue abolishes the receptor-recognition site of alpha 2-macroglobulin complexes. FEBS Lett 1982; 137: 241-244.
221. Salvesen G, Quan LT, Enghild JJ et al. Expression of a functional alpha-macroglobulin receptor binding domain in Escherichia coli. FEBS Lett 1992; 313: 198-202.
222. Nielsen KL, Holtet TL, Etzerodt M et al. Identification of residues in alpha-macroglobulins important for binding to the alpha2-macroglobulin receptor/Low density lipoprotein receptor-related protein. J Biol Chem 1996; 271: 12909-12912.
223. Howard GC, Yamaguchi Y, Misra UK et al. Selective mutations in cloned and expressed alpha-macroglobulin receptor binding fragment alter binding to either the alpha2- macroglobulin signaling receptor or the low density lipoprotein receptor-related protein/alpha2-macroglobulin receptor. J Biol Chem 1996; 271: 14105-14111.
224. Wun TC, Kretzmer KK, Girard TJ, MiletichJP, Broze GJ, Jr. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. J Biol Chem 1988; 263: 6001-6004.
225. Girard TJ, Warren LA, Novotny WF et al. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 1989; 338: 518-520.
226. Wesselschmidt R, Likert K, Girard T, Wun TC, Broze GJ, Jr. Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of factor Xa. Blood 1992; 79: 2004-2010.
227. Wesselschmidt R, Likert K, Huang Z, MacPhail L, Broze GJ, Jr. Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin. Blood Coagulation & Fibrinolysis 1993; 4: 661-669.
228. Warshawsky I, Bu G, Mast A, Saffitz JE, Broze GJ, Jr., Schwartz AL. The carboxy terminus of tissue factor pathway inhibitor is required for interacting with hepatoma cells in vitro and in vivo. J Clin Invest 1995; 95: 1773-1781.
229. Strickland DK, Ashcom JD, Williams S et al. Primary structure of alpha 2-macroglobulin receptor-associated protein. Human homologue of a Heymann nephritis antigen. J Biol Chem 1991; 266: 13364-13369.
230. Pietromonaco S, Kerjaschki D, Binder S, Ullrich R, Farquhar MG. Molecular cloning of a cDNA encoding a major pathogenic domain of the Heymann nephritis antigen gp330. PNAS 1990; 87: 1811-1815.
231. Medh JD, Fry GL, Bowen SL, Pladet MW, Strickland DK, Chappell DA. The 39-kDa receptor-associated protein modulates lipoprotein catabolism by binding to LDL receptors. J Biol Chem 1995; 270: 536-540.
232. Bu G, Geuze HJ, Strous GJ, Schwartz AL. 39 kDa receptor-associated protein is an ER resident protein and molecular chaperone for LDL receptor-related protein. EMBO J 1995; 14: 2269-2280.
233. Bu G, Rennke S, Geuze HJ. ERD2 proteins mediate ER retention of the HNEL signal of LRP's receptor-associated protein (RAP). J Cell Sci 1997; 110: 65-73.
234. Bu G, Maksymovitch EA, Geuze H, Schwanz AL. Subcellular localization and endocytic function of low density lipoprotein receptor-related protein in human glioblastoma cells. J Biol Chem 1994; 269: 29874-29882.
235. Willnow TE, Armstrong SA, Hammer RE, Herz J. Functional expression of low density lipoprotein receptor-related protein is controlled by receptor-associated protein in vivo. PNAS 1995; 92: 4537-4541.
236. Willnow TE, Rohlmann A, Horion J et al. RAP, a specialized chaperone, prevents ligand-induced ER retention and degradation of LDL receptor-related endocytic receptors. EMBO J 1996; 15: 2632-2639.
237. Orlando RA, Farquhar MG. Functional domains of the receptor-associated protein (RAP). PNAS 1994; 91: 3161-3165.
238. Iadonato SP, Bu G, Maksymovitch EA, Schwartz AL. Interaction of a 39 kDa protein with the low-density-Kpoprotein-receptor-related protein (LRP) on rat hepatoma cells. Biochem J 1993; 296: 867-875.
239. Warshawsky I, Bu G, Schwartz AL. Binding analysis of amino-terminal and carboxyl-terminal regions of the 39-kDa protein to the low density lipoprotein receptor-related protein. J Biol Chem 1994; 269: 3325-3330.
240. Warshawsky I, Bu G, Schwartz AL. Identification of domains on the 39-kDa protein that inhibit the binding of ligands to the low density lipoprotein receptor-related protein. J Biol Chem 1993; 268: 22046-22054.
241. Nielsen MS, Nykjær A, Warshawsky I, Schwartz AL, Gliemann J. Analysis of ligand binding to the alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that lipoprotein lipase and the carboxyl-terminal domain of the receptor-associated protein bind to the same site. J Biol Chem 1995; 270: 23713-23719.
242. Warshawsky I, Bu G, Schwartz AL Sites within the 39-kDa protein important for regulating ligand binding to the low-density lipoprotein receptor-related protein. Biochemistry 1995; 34: 3404-3415.
243. Ellgaard L, Holtet TL, Nielsen PR, Etzerodt M, Gliemann J, Thogersen HC. Dissection of the domain architecture of the alpha2-macroglobulin-receptor-associated protein. Eur J Biochem 1997; 244: 544-551.
244. Nielsen PR, Ellgaard L, Etzerodt M, Thogersen HC, Poulsen FM. The solution structure of the N-terminal domain of alpha(2)-macroglobulin receptor-associated protein. PNAS 1997; 94: 7521-7525.
245. Sottile J, Selegue J, Mosher DF. Synthesis of truncated amino-terminal trimers of thrombospondin. Biochemistry 1991; 30: 6556-6562.
246. Lawler J, Hynes RO. The structure of human thrombospondin, an adhesive glycoprotein with multiple calcium-binding sites and homologies with several different proteins. J Cell Biol 1986; 103: 1635-1648.
247. Bork P. The modular architecture of vertebrate collagens. FEBS Lett 1992; 307: 49-54.
248. Chen H, Sottile J, Strickland DK, Mosher DF. Binding and degradation of thrombospondin-1 mediated through heparan sulphate proteoglycans and low-density-lipoprotein receptor-related protein: localization of the functional activity to the trimeric N-terminal heparin-binding region of thrombospondin-1. Biochem J 1996; 318: 959-963.
249. Mikhailenko I, Krylov D, Argraves KM, Roberts DD, Liau G, Strickland DK. Cellular internalization and degradation of thrombospondin-1 is mediated by the amino-terminal heparin binding domain (HBD). High affinity interaction of dimeric HBD with the low density lipoprotein receptor-related protein. J Biol Chem 1997; 272: 6784-6791.
250. Thompson MR, Forristal J, Kauffmann P et al. Isolation and characterization of Pseudomonas aeruginosa exotoxin A hinding glycoprotein from mouse LM cells. J Biol Chem 1991; 266: 2390-2396.
251. Pastan I, Willingham MC, FitzGerald DJ. Immunotoxins. Cell 1986; 47: 641-648.
252. Allured VS, Collier RJ, Carroll SF, McKay DB. Structure of exotoxin A of Pseudomonas aeruginosa at 3.0-Angstrom resolution. PNAS 1986; 83: 1320-1324.
253. Hwang J, FitzGerald DJ, Adhya S, Pastan I. Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli. Cell 1987; 48: 129-136.
254. Gray GL, Smith DH, Baldridge JS et al. Cloning, nucleotide sequence, and expression in Escherichia coli of the exotoxin A structural gene of Pseudomonas aeruginosa. PNAS 1984; 81: 2645-2649.
255. Siegall CB, Chaudhary VK, FitzGerald DJ, Pastan I. Functional analysis of domains II, Ib, and III of Pseudomonas exotoxin. J Biol Chem 1989; 264: 14256-14261.
256. Chaudhary VK, Xu YH, FitzGerald D, Adhya S, Pastan I. Role of domain II of Pseudomonas exotoxin in the secretion of proteins into the periplasm and medium by Escherichia coli. PNAS 1988; 85: 2939-2943.
257. Jinno Y, Chaudhary VK, Kondo T, Adhya S, FitzGerald DJ, Pastan I. Mutational analysis of domain I of Pseudomonas exotoxin. Mutations in domain I of Pseudomonas exotoxin which reduce cell binding and animal toxicity. J Biol Chem 1988; 263: 13203-13207.
258. Chaudry GJ, Wilson RB, Draper RK, Clowes RC. A dipeptide insertion in domain I of exotoxin A that impairs receptor binding. J Biol Chem 1989; 264: 15151-15156.
259. Pirker R, FitzGerald DJ, Hamilton TC, Ozols RF, Willingham MC, Pastan I. Anti-transferrin receptor antibody linked to Pseudomonas exotoxin as a model immunotoxin in human ovarian carcinoma cell lines. Cancer Research 1985; 45: 751-757.
260. Cerami C, Frevert U, Sinnis P et al. The basolateral domain of the hepatocyte plasma membrane bears receptors for the circumsporozoite protein of Plasmodium falciparum sporozoites. Cell 1992; 70: 1021-1033.
261. Aley SB, Bates MD, Tarn JP, Hollingdale MR. Synthetic peptides from the circumsporozoite proteins of Plasmodium falciparum and Plasmodium knowlesi recognize the human hepatoma cell line HepG2-A16 in vitro. J Exp Med 1986; 164; 1915-1922.
262. Metz-Boutique MH, Jolies J, Mazurier J et al. Human lactotransferrin: amino acid sequence and structural comparisons with other transferrins. Eur J Biochem 1984; 145: 659-676.
263. Argraves KM, Kozarsky KF, Fallon JT et al. The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor. J Clin Invest 1997; 100: 2170-2181.
264. Kounnas MZ, Loukinova EB, Stefansson S et al. Identification of glycoprotein 330 as an endocytic receptor for apolipoprotein J/clusterin [published erratum appears in J Biol Chem 1995 Sep 29; 270(30): 23234]. J Biol Chem 1995; 270 13070-13075.
265. Medh JD, Bowen SL, Fry GL et al. Lipoprotein lipase binds to low density lipoprotein receptors and induces receptor-mediated catabolism of very low density Hpoproteins in vitro. J Biol Chem 1996; 271: 17073-17080.
266. Stefansson S, Kounnas MZ, Henkin J et al. gp330 on type II pneumocytes mediates endocytosis leading to degradiation of pro-urokinase, plasminogen activator inhibitor-1 and urokinase-plasminogen activator inhibitor-1 complex. J Cell Sci 1995; 108: 2361-2368.
267. Moestrup SK, Nielsen S, Andreasen P et al. Epithelial glycoprotein-330 mediates endocytosis of plasminogen activator-plasminogen activator inhibitor type-1 complexes. J Biol Chem 1993; 268: 16564-16570.
268. Heegaard CW, Simonsen AC, Oka K et al. Very low density lipoprotein receptor binds and mediates endocytosis of urokinase-type plasminogen activator-type-1 plasminogen activator inhibitor complex. J Biol Chem 1995; 270: 20855-20861.
269. Storm D, Herz J, Trinder P, Loos M. Cl inhibitor-C1s complexes are internalized and degraded by the low density lipoprotein receptor-related protein. J Biol Chem 1997; 272: 31043-31050.
270. Poller W, Willnow TE, Hilpert J, Herz J. Differential recognition of alpha 1-antitrypsin-elastase and alpha 1-antichymotrypsin-cathepsin G complexes by the low density lipoprotein receptor-related protein. J Biol Chem 1995; 270: 2841-2845.
271. Van Leuven F, Cassiman JJ, Van den Berghe H. Human pregnancy zone protein and alpha 2-macroglobulin. High-affinity binding of complexes to the same receptor on fibroblasts and characterization by monoclonal antibodies. J Biol Chem 1986; 261: 16622-16625.
272. Kanalas JJ, Makker SP. Analysis of a 45-kDa protein that binds to the Heymann nephritis autoantigen GP330. J Biol Chem 1993; 268: 8188-8192.
273. Battey FD, Gåfvels ME, FitzGerald DJ et al. The 39-kDa receptor-associated protein regulates ligand binding by the very low density lipoprotein receptor. J Biol Chem 1994; 269: 23268-23273.